{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:32:27Z","timestamp":1793316747015,"version":"4.5.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.kint.2020.01.030","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T05:02:14Z","timestamp":1589864534000},"page":"1104-1106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?"],"prefix":"10.1016","volume":"97","author":[{"given":"Michelle N.","family":"Rheault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Smoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2020.01.030_bib1","first-page":"203","article-title":"Hereditary nephropathy (Alport syndrome): correlation of clinical data with glomerular basement membrane alterations","volume":"13","author":"Rumpelt","year":"1980","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2020.01.030_bib2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s004670050451","article-title":"Chronology of renal scarring in males with Alport syndrome","volume":"12","author":"Kashtan","year":"1998","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2020.01.030_bib3","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","article-title":"A\u00a0multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport\u2019s syndrome","volume":"97","author":"Gross","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.01.030_bib4","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","article-title":"Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome","volume":"63","author":"Gross","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.01.030_bib5","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.01.030_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2020.01.030_bib7","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1681\/ASN.2018010036","article-title":"Early proteinuria lowering by angiotensin-converting enzyme inhibition predicts renal survival in children with CKD","volume":"29","author":"van den Belt","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.01.030_bib8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.tips.2019.07.012","article-title":"Alport syndrome therapeutics: ready for prime-time players","volume":"40","author":"Omachi","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.kint.2020.01.030_bib9","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.kint.2019.05.033","article-title":"Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?","volume":"96","author":"Ito","year":"2019","journal-title":"Kidney Int"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253820301472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253820301472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:55:54Z","timestamp":1758761754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253820301472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0085253820301472"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2020.01.030","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2020.01.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.12.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}